Gustave Roussy has arranged that each of its research departments provides technical resources in common, the benefits of which are shared between all of its component research units. This mutual arrangement encourages interactions between departments and continuity within the research process.
These platforms are brought together within the UMS AMMICa (CNRS UMS 3655 / Inserm US 23):
Toppaldoddi KR, da Costa Cacemiro M, Bluteau O, Panneau-Schmaltz B, Pioch A, Muller D, Villeval JL, Raslova H, Constantinescu SN, Plo I, Vainchenker W, Marty C. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. Oncogene. 2019 Mar;38(10):1651-1660.
The Laboratory of Immunomonitoring in Oncology (LIO), created at the end of 2014, is a translational research unit. The main objective of the laboratory is to identify blood or tumor biomarkers that can predict the response or resistance to anti-tumor immunotherapies, as well as the emergence of some immunological adverse effects that may be linked to these treatments. Another objective is to understand the mechanisms of action of anti-tumor immunotherapies.